Article

COA Commends Senate Finance Committee for PBM Hearing

The Community Oncology Alliance (COA) is offering praise for the Senate Finance Committee over its pharmacy benefit manager (PBM) hearing, which COA called a reminder that PBMs refuse to acknowledge their role in rising drug costs.

The Community Oncology Alliance (COA) is offering praise for the Senate Finance Committee over its pharmacy benefit manager (PBM) hearing, which COA called a reminder that PBMs refuse to acknowledge their role in rising drug costs. COA also recommended additional work be done to shine a light on PBM abuses in delaying and/or denying cancer treatment for patients and that the House Energy & Commerce Committee hold hearings focused solely on PBMs.

COA voiced its support for the administration's proposal to eliminate PBM rebates in Medicare, as well as legislation to reign in PBM abuses, which includes recent legislation proposed that would bring ptice transparency to the prescription drug market and pass discuounts to consumers. Read the full press release.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Cathy Eng, MD, FACP, FASCO
Dr Margrit Wiesendanger
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Margrit Wiesendanger
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo